How to buy Aptevo Therapeutics (APVO) stock

Aptevo Therapeutics Inc is a biotechnology business based in the US. Aptevo Therapeutics shares (APVO) are listed on the NASDAQ and all prices are listed in US Dollars. Aptevo Therapeutics employs 58 staff and has a trailing 12-month revenue of around 0.00.

Aptevo Therapeutics stock price (NASDAQ: APVO)

Use our graph to track the performance of APVO stocks over time.

Aptevo Therapeutics shares at a glance

• Key figures

Information last updated 2021-07-22.

Latest market close	$26.12
52-week range	$6.17 - $60.00
50-day moving average	$23.61
200-day moving average	$28.84
Wall St. target price	$61.00
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-1.76

Buy Aptevo Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Aptevo Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Aptevo Therapeutics Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Aptevo Therapeutics price performance over time

Historical closes compared with the close of $26.12 from 2021-05-28

1 week (2021-07-15)	N/A
1 month (2021-06-25)	4.82%
3 months (2021-04-26)	2.83%
6 months (2021-01-22)	N/A

1 year (2020-07-22)	N/A
2 years (2019-07-22)	N/A
3 years (2018-07-22)	N/A
5 years (2016-07-22)	N/A

Aptevo Therapeutics financials

Revenue TTM	$6.7 million
Gross profit TTM	$-13,543,000
Return on assets TTM	-35.59%
Return on equity TTM	-222.89%
Profit margin	0%
Book value	$2.36
Market capitalisation	$92.4 million

TTM: trailing 12 months

Shorting Aptevo Therapeutics shares

There are currently 110,573 Aptevo Therapeutics shares held short by investors – that's known as Aptevo Therapeutics's "short interest". This figure is 5.2% up from 105,083 last month.

There are a few different ways that this level of interest in shorting Aptevo Therapeutics shares can be evaluated.

Aptevo Therapeutics's "short interest ratio" (SIR)

Aptevo Therapeutics's "short interest ratio" (SIR) is the quantity of Aptevo Therapeutics shares currently shorted divided by the average quantity of Aptevo Therapeutics shares traded daily (recently around 121508.79120879). Aptevo Therapeutics's SIR currently stands at 0.91. In other words for every 100,000 Aptevo Therapeutics shares traded daily on the market, roughly 910 shares are currently held short.

However Aptevo Therapeutics's short interest can also be evaluated against the total number of Aptevo Therapeutics shares, or, against the total number of tradable Aptevo Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Aptevo Therapeutics's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Aptevo Therapeutics shares in existence, roughly 20 shares are currently held short) or 0.0511% of the tradable shares (for every 100,000 tradable Aptevo Therapeutics shares, roughly 51 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Aptevo Therapeutics.

Find out more about how you can short Aptevo Therapeutics stock.

Aptevo Therapeutics share dividends

We're not expecting Aptevo Therapeutics to pay a dividend over the next 12 months.

Have Aptevo Therapeutics's shares ever split?

Aptevo Therapeutics's shares were split on a 1:14 basis on 26 March 2020. So if you had owned 14 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Aptevo Therapeutics shares – just the quantity. However, indirectly, the new 1300% higher share price could have impacted the market appetite for Aptevo Therapeutics shares which in turn could have impacted Aptevo Therapeutics's share price.

Aptevo Therapeutics share price volatility

Over the last 12 months, Aptevo Therapeutics's shares have ranged in value from as little as $6.17 up to $60. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Aptevo Therapeutics's is 7.1207. This would suggest that Aptevo Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Aptevo Therapeutics overview

Aptevo Therapeutics Inc. , a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1/1b clinical trial for acute myelogenous leukemia and myelodysplastic syndrome. The company's preclinical candidates also include ALG. APV-527, an investigational bispecific ADAPTIR candidate that features a mechanism of action to target 4-1BB (CD137) and 5T4, a tumor antigen expressed in various types of cancers; and APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40. It is also developing APVO442, a bispecific candidate based on the ADAPTIR-FLEX platform technology to enhance biodistribution of drugs to PSMA positive tumors for treatment of prostate cancer; and other pre-clinical development stage therapeutics focused on hematologic and solid tumors. It has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.

Frequently asked questions

What percentage of Aptevo Therapeutics is owned by insiders or institutions?
Currently 5.82% of Aptevo Therapeutics shares are held by insiders and 67.317% by institutions. How many people work for Aptevo Therapeutics?
Latest data suggests 58 work at Aptevo Therapeutics. When does the fiscal year end for Aptevo Therapeutics?
Aptevo Therapeutics's fiscal year ends in December. Where is Aptevo Therapeutics based?
Aptevo Therapeutics's address is: 2401 4th Avenue, Seattle, WA, United States, 98121 What is Aptevo Therapeutics's ISIN number?
Aptevo Therapeutics's international securities identification number is: US03835L2079 What is Aptevo Therapeutics's CUSIP number?
Aptevo Therapeutics's Committee on Uniform Securities Identification Procedures number is: 03835L108